Zenapax data

PDLI and partner Hoffmann-La Roche published an abstract of a Phase I trial of Zenapax that will be presented at the American Society of Transplant Physicians meeting on May 16. Of 12 patients treated, only one experienced a rejection episode, which was reversible.

Four patients were given doses of 0.5 mg/kg/week; two received 1 mg/kg/week; three were given 0.5 mg/kg every other week; and three were given 1 mg/kg every other week. The first dose was given 12 hours prior to transplant and four additional doses were given after transplantation. ...